Literature DB >> 31162260

Risk Factors for Indeterminate Response After Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer.

Eugene Jeong1, Joon-Kee Yoon1, Su Jin Lee1, Euy Young Soh2, Jeonghun Lee2, Young-Sil An1.   

Abstract

PURPOSE: We investigated the risk factors of indeterminate response (IDR) in patients who underwent recombinant human thyroid-stimulating hormone (rhTSH)-aided radioactive iodine therapy (RAIT).
METHODS: A total of 128 patients with papillary thyroid cancer were included in this retrospective study. The patients were classified into excellent response and IDR groups based on follow-up diagnostic whole-body scintigraphy (WBS) and TSH-stimulated thyroglobulin (Tg). Indeterminate response was defined as the presence of a faint uptake in the thyroid bed on the diagnostic WBS or a TSH-stimulated Tg detectable, but less than 10 ng/mL. Parameters that act as significant risk factors for IDR, including age, sex, stage, surgeon, time interval between surgery and RAIT, post-treatment WBS finding, urine iodine-to-creatinine ratio, TSH-unstimulated Tg, and rhTSH-stimulated Tg, were analyzed using a Cox proportional hazards regression method.
RESULTS: After treatment, 64 patients showed IDR. Recombinant human TSH-stimulated Tg was the only independent risk factor for predicting IDR. Patients with an rhTSH-stimulated Tg greater than 2 ng/mL prior to RAIT were 3.75 times more likely (95% confidence interval, 1.61-8.72) to have an IDR than those with a lower rhTSH-stimulated Tg (≤2 ng/mL).
CONCLUSIONS: Pre-RAIT TSH-stimulated Tg levels are a risk factor for IDR after RAIT.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31162260     DOI: 10.1097/RLU.0000000000002653

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

1.  Prognostic Factors for Excellent Response to Initial Therapy in Patients With Papillary Thyroid Cancer From a Prospective Multicenter Study.

Authors:  Wen-Wu Dong; Da-Lin Zhang; Liang He; Liang Shao; Zhi-Hong Wang; Cheng-Zhou Lv; Ping Zhang; Tao Huang; Hao Zhang
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

2.  Differential distribution and prognostic value of CD4+ T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes.

Authors:  Zhi-Yong Shi; Sheng-Xiao Zhang; Cai-Hong Li; Di Fan; Yan Xue; Zhe-Hao Cheng; Li-Xiang Wu; Ke-Yi Lu; Zhi-Fang Wu; Xiao-Feng Li; Hai-Yan Liu; Si-Jin Li
Journal:  Front Immunol       Date:  2022-08-26       Impact factor: 8.786

3.  Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer.

Authors:  Aleksandra Ledwon; Ewa Paliczka-Cieślik; Aleksandra Syguła; Tomasz Olczyk; Aleksandra Kropińska; Agnieszka Kotecka-Blicharz; Kornelia Hasse-Lazar; Aneta Kluczewska-Gałka; Barbara Jarząb; Daria Handkiewicz-Junak
Journal:  Ann Nucl Med       Date:  2021-08-07       Impact factor: 2.668

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.